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In this study, Rong et al confirm the role of ACAT-1 in the formation of SMC foam cells and show that SMCs are resistant to the toxic effects of ACAT inhibition and free cholesterol ( Figure) . 9 SMCs that were treated with cholesterol cyclodextrin complexes produced foam cells with lipid droplets and elevated levels of cholesteryl esters. The ACAT inhibitor F-1394 was able to block the accumulation of lipid droplets. More importantly, the authors found a significant difference between SMC and macrophages with regard to cholesterol-induced toxicity. ACAT inhibition that caused cholesterol toxicity in cholesterol-loaded macrophages was apparently well tolerated cholesterol-loaded SMC. This finding provides a potential explanation for how ACAT inhibition can cause a decrease in the size of the macrophage foam-cell lesion and an apparent increase in the number of SMCs in the plaque. 5 These interesting results might have been partly influenced by the unique loading method, which redistributes large amounts of cholesterol to the plasma membrane. It is not known whether cholesterol that enters through the plasma membrane has the same toxic potential as cholesterol that enters by receptor-mediated uptake of modified lipoproteins or phagocytic uptake of cellular debris. As for the resistance of SMC foam cells to toxicity, it is possible that relative to macrophages SMC have less cholesterol routed to toxic pools or more efficient removal of cholesterol from these pools.
The exact nature of cytotoxic pools of cholesterol is unknown. Although these pools are associated with both plasma membrane and endoplasmic reticulum, the specific mechanisms of their formation and cellular topology remain largely unknown. 10, 11 Mounting evidence suggests that different cell types in the plaque deal differently with the cholesterol burden. Akishima et al have recently reported that in human atherosclerotic lesions macrophages are more susceptible than SMCs to apoptosis. 12 Guyton et al have shown that antioxidants provide SMCs with partial protection from oxLDL-induced toxicity. 13 Yu et al found that macrophages are more susceptible than SMCs to toxicity induced by loading cells with cholesterol from chylomicron remnants. 14 In that study, superoxide free radical production was the reported mechanism of toxicity, suggesting that cellular lipid peroxidation is a consequence of excess free cholesterol. Factors that could play a role in the mechanism of the relative resistance of SMCs to cholesterol toxicity include: (1) production of endogenous oxysterols and activation of LXR; (2) degree of lipid peroxidation; and (3) cell-specificity of the signaling pathways downstream of free cholesterol accumulation.
Resistance to the cytotoxic effects of free cholesterol could make SMCs an important regulator of the evolution of the plaque, providing a second wave of protection when cholesterol burden continues to increase and macrophage foam-cells succumb to cholesterol toxicity in the plaque core. When the results of this study are considered in combination with a previous study from this group, 15 a compelling argument can be made for the potential of SMCs to step in as functioning phagocytes under conditions where macrophages lose viability. More support for the idea that SMC proliferation provides a second wave of vascular protection from the insult comes from a study of Wolfbauer et al, who produced foam cells by loading SMCs with lipid droplets from lysed macrophage foam cells. 16 The presence of extracellular lipid droplets in atherosclerotic lesions in vivo suggests that this in vitro approach may parallel a physiological scenario by which SMC foam cells are produced by ingestion of cellular debris and lipid droplets of macrophage derivation. These studies support the speculation that SMCs may be particularly well suited to clean up the mess that results from the death of macrophage foam cells. Even though it would seem intuitive that freshly recruited monocytes and macrophages have a mandate to perform this role, thus thickening the atheroma with new layers of foam cells, it is possible that SMCs become the phagocyte of choice because of their ability to remain viable under severe lipid stress.
The resistance of SMCs to cholesterol toxicity may represent better compensatory changes in lipid homeostasis compared with macrophages. Compensatory changes in macrophages include phospholipid synthesis and cytoplasmic whorls of newly synthesized phospholipid in membranes, as an increased content in phosphatidylcholine stabilizes membrane cholesterol. 17, 18 It would be interesting to know whether SMCs use a similar compensatory mechanisms or if they have unique pathways of resistance to cholesterolinduced cytotoxicity.
In recent studies from our laboratory, we have described the atherogenic effects of ACAT-1 deficiency in macrophages. 8, 19 The study by Rong et al and other studies have confirmed the potential for ACAT inhibition to promote foam cell macrophage death. 6, 7, 9 Rong et al have re-opened the door to the use of ACAT inhibitors in atherogenesis, as SMC proliferation is prevalent in advanced-stage atherosclerosis and in restenosis. 20 In light of the current study, it seems that in circumstances where SMCs represent a large portion of the plaque, ACAT-1 inhibition may serve a therapeutic role as direct antiatherosclerotic agent.
ACAT inhibitors have had mixed results, with protective effects in atherosclerosis in vivo and potentially toxic consequences in macrophages in vitro. Resistance of SMC-derived foam cells to cholesterol toxicity provides a working explanation for these results and puts ACAT-1 inhibition targeted to the SMCs in the crosshairs as a potential therapeutic target in atherosclerosis. 
